Before

During the development of the synthesis process for pharmaceutical APIs, it is critical to ensure that elemental impurities associated with metal catalysts are scavenged prior to downstream processing of the drug substance. Traditionally, the effectiveness of scavenging processes has been determined using plasma-based instrumental techniques, such as ICP-OES or ICPMS. Although these methods provide a means of accurately detecting very low concentrations of elemental impurities, they can be time-consuming and costly to apply, delaying process development decisions.

With the costs and risks associated with drug development steadily increasing, pharmaceutical companies must focus on how to improve efficiency in the research and development phases. This webinar will explore how and why pharmaceutical process chemists should leverage X-Ray Fluorescence (XRF) as a rapid, easy-to-use, easy-to-deploy elemental impurity screening tool in support of drug synthesis process development. We will present case studies which show how XRF can be applied as a costeffective and time-effective means of performing metal catalyst scavenger studies, supporting optimization of the effectiveness and efficiency of drug synthesis processes.

After

The life-changing magic of X-Ray Fluorescence. Detecting impurities in pharmaceutical APIs in minutes instead of hours.

Traditionally, the best way to check for elemental impurities was with plasma-based techniques such as ICP-OES or ICP-MS. They’re accurate, but time-consuming and costly.

There is a faster, easier and more cost-effective way: X-Ray Fluorescence (XRF). It’s simpler to deploy and gives you results in minutes, not hours.

So the opportunities to speed up development decisions can be huge.

What we’ll cover in this webinar:

• How XRF could work as part of your R&D process.
• Case studies about how other process chemists are integrating XRF’s speed and costeffectiveness in their labs.